Prime Medicine closes public offering with full option exercise for about $143.7 million gross
FROM THE WIRE · MANILATIMES.NET
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishIssuing about 41 million shares at $3.50 brings dilution for existing shareholders.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01A total of 41,071,428 shares were sold, including 5,357,142 from the underwriters' option.
- 02The public offering price was $3.50 per share.
- 03Gross proceeds were about $143.7 million before fees and expenses.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets